Yip1 domain family member 7Genealiases: FinGER9 · YIPFalpha1b · Yip1b
Q-omics provides the consensus-scored YIPF7 profile across patient tissues and cancer cell-line models. YIPF7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, YIPF7 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, YIPF7 RNA expression shows 12,317 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, THCA, and THYM as cancer lineages where YIPF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YIPF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YIPF7 survival associations across molecular data types. YIPF7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YIPF7 RNA expression–survival associations across cancer types. High YIPF7 expression shows unfavorable associations in READ, UCEC, KIRC, BLCA, LIHC and KICH. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify READ as the clearest survival context for YIPF7 RNA expression.
This table summarizes YIPF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for YIPF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YIPF7 shows lower tumor expression in THCA, KICH, HNSC, UCEC and BRCA and higher tumor expression in PAAD. The THCA box plot shows higher YIPF7 RNA expression in normal versus tumor tissue (log2 FC = −0.264, t-test p < 0.001).
This table shows molecular features associated with YIPF7 in patient tissues and cancer cell lines. In patient samples, YIPF7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, YIPF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
